In preclinical studies, TIM-3 aptamers have been shown to enhance immune responses and reverse T-cell exhaustion in cancer models, particularly when used alongside other checkpoint inhibitors, such as PD-1/PD-L1 blockers. This evidence concerns the gene HAVCR2 and cancer.